Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature. / Jeppesen, Johanne Bakker; Østerlind, Kell.

In: Clinical Colorectal Cancer, Vol. 10, No. 4, 12.2011, p. 348-52.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jeppesen, JB & Østerlind, K 2011, 'Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature', Clinical Colorectal Cancer, vol. 10, no. 4, pp. 348-52. https://doi.org/10.1016/j.clcc.2011.06.003, https://doi.org/10.1016/j.clcc.2011.06.003

APA

Jeppesen, J. B., & Østerlind, K. (2011). Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature. Clinical Colorectal Cancer, 10(4), 348-52. https://doi.org/10.1016/j.clcc.2011.06.003, https://doi.org/10.1016/j.clcc.2011.06.003

Vancouver

Jeppesen JB, Østerlind K. Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature. Clinical Colorectal Cancer. 2011 Dec;10(4):348-52. https://doi.org/10.1016/j.clcc.2011.06.003, https://doi.org/10.1016/j.clcc.2011.06.003

Author

Jeppesen, Johanne Bakker ; Østerlind, Kell. / Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature. In: Clinical Colorectal Cancer. 2011 ; Vol. 10, No. 4. pp. 348-52.

Bibtex

@article{138ac302e1304ce8a0f56503c903e566,

title = "Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature",

abstract = "There is limited experience in treating advanced colorectal cancer diagnosed during pregnancy because it is a rare occurrence; however, the incidence of colorectal cancer complicating pregnancy is expected to increase in the future. The combination of cancer and pregnancy is complicated and causes many dilemmas and concerns for the physician and patient. A delay in treatment may compromise maternal survival; however, therapy for the cancer may be harmful to the fetus. We present a case of a 26-year-old woman pregnant with twins who was diagnosed with metastatic colon cancer and treated with 5-fluorouracil, leukovorin, and oxaliplatin (FOLFOX) from 13 weeks gestational age to birth. The patient gave birth to healthy twins without malformations at 33 weeks gestational age. At follow-up examination, the 2-year-old twins are developing normally. The patient herself died 1 year after the initial cancer diagnosis. This shows a case in which the administration of FOLFOX during the second and third trimester of pregnancy caused no fetal harm. These findings are similar to those of previous studies in which systemic chemotherapy administered during the second and third trimester was relatively safe. However, we know that chemotherapy should be avoided during the first trimester.",

author = "Jeppesen, {Johanne Bakker} and Kell {\O}sterlind",

year = "2011",

month = dec,

doi = "10.1016/j.clcc.2011.06.003",

language = "English",

volume = "10",

pages = "348--52",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "4",

}

RIS

TY - JOUR

T1 - Successful twin pregnancy outcome after in utero exposure to FOLFOX for metastatic colon cancer: a case report and review of the literature

AU - Jeppesen, Johanne Bakker

AU - Østerlind, Kell

PY - 2011/12

Y1 - 2011/12

N2 - There is limited experience in treating advanced colorectal cancer diagnosed during pregnancy because it is a rare occurrence; however, the incidence of colorectal cancer complicating pregnancy is expected to increase in the future. The combination of cancer and pregnancy is complicated and causes many dilemmas and concerns for the physician and patient. A delay in treatment may compromise maternal survival; however, therapy for the cancer may be harmful to the fetus. We present a case of a 26-year-old woman pregnant with twins who was diagnosed with metastatic colon cancer and treated with 5-fluorouracil, leukovorin, and oxaliplatin (FOLFOX) from 13 weeks gestational age to birth. The patient gave birth to healthy twins without malformations at 33 weeks gestational age. At follow-up examination, the 2-year-old twins are developing normally. The patient herself died 1 year after the initial cancer diagnosis. This shows a case in which the administration of FOLFOX during the second and third trimester of pregnancy caused no fetal harm. These findings are similar to those of previous studies in which systemic chemotherapy administered during the second and third trimester was relatively safe. However, we know that chemotherapy should be avoided during the first trimester.

AB - There is limited experience in treating advanced colorectal cancer diagnosed during pregnancy because it is a rare occurrence; however, the incidence of colorectal cancer complicating pregnancy is expected to increase in the future. The combination of cancer and pregnancy is complicated and causes many dilemmas and concerns for the physician and patient. A delay in treatment may compromise maternal survival; however, therapy for the cancer may be harmful to the fetus. We present a case of a 26-year-old woman pregnant with twins who was diagnosed with metastatic colon cancer and treated with 5-fluorouracil, leukovorin, and oxaliplatin (FOLFOX) from 13 weeks gestational age to birth. The patient gave birth to healthy twins without malformations at 33 weeks gestational age. At follow-up examination, the 2-year-old twins are developing normally. The patient herself died 1 year after the initial cancer diagnosis. This shows a case in which the administration of FOLFOX during the second and third trimester of pregnancy caused no fetal harm. These findings are similar to those of previous studies in which systemic chemotherapy administered during the second and third trimester was relatively safe. However, we know that chemotherapy should be avoided during the first trimester.

U2 - 10.1016/j.clcc.2011.06.003

DO - 10.1016/j.clcc.2011.06.003

M3 - Journal article

VL - 10

SP - 348

EP - 352

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 4

ER -

ID: 40207110

Department of Biomedical Sciences